Lunai Bioworks Inc (LNAI) Stock Price, Quote & News

Company Profile

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform...

Industry: Biotechnology

Sector: Healthcare

Phone: 305 918 1980

Website: www.lunaibioworks.com

Address:

2080 Century Park East, Suite 906, Los Angeles, United States

IcePhoenix Apr. 25 at 3:47 AM

MITQ 🚨Great setup into next week, keep eyes on this one 🚀 Low float + active news cycle + volume building = squeeze conditions forming. We’ve seen this movie before. Feels like news may be coming on MITQ: 🔹 Real hidden gem, has more revenue than market cap 🔹 Positioned in cinema digital transformation — software, audio/visual, and immersive experiences 🍿 🔹 History of sharp spikes — known for big moves when volume hits. $FLWS $WIMI $ATCH $LNAI ww /.

0 · Reply

RoyalImperial Apr. 24 at 9:24 PM

MITQ looking ready, keep eyes on this one. Latest news + contracts rolling in Low float (~sub 10M) NO dilution Record earnings trend 📈. MITQ super undervalued-The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $ITOC $LNAI $FCHL $LZMH ...1

0 · Reply

sidhero Apr. 24 at 4:36 PM

$LNAI what happened it was doing so well

0 · Reply

Kesiya Apr. 24 at 1:32 PM

$LNAI If it has already exited, do not buy again, friends (wait for a new post)/ but if it is still there, set a stop-loss at 3-5%.,

0 · Reply

Jumpmanz Apr. 24 at 1:28 PM

$ELPW $FCHL $ITOC $LNAI $SCNI

1 · Reply

Kesiya Apr. 24 at 1:23 PM

$FCHL $ITOC $LNAI /Get ready to travel+

1 · Reply

xMrCommonwealth Apr. 24 at 1:22 PM

$FCHL $SCNI $ELPW $ITOC $LNAI

1 · Reply

DavidScott Apr. 24 at 12:57 PM

$FCHL $SCNI $ELPW $ITOC $LNAI = Morning Movers 🔥📈💪

0 · Reply

Olivia_Strickland Apr. 24 at 12:46 PM

$LNAI premarket pop, up 13% on a $11M cap name. Volume already ripping at 4.6x the 10-day avg with 1.4B shares crossing. Still 95% off the 52w high and down 67% over 3 months, so this is a bounce off deep lows. Gotta see if bulls can hold any reclaim into the open.

1 · Reply

Luvstocks26 Apr. 24 at 11:54 AM

$LNAI Lunai Bioworks Inc. (NASDAQ:LNAI) on Thursday announced that it had executed a binding transaction worth $20 million with Clemann Group for its blood-brain barrier technology. LNAI shares surged 15.29% in pre-market trading.

0 · Reply

Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships

Apr 7, 2026, 9:05 AM EDT - 17 days ago

Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion

Mar 26, 2026, 8:50 AM EDT - 4 weeks ago

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications

Mar 19, 2026, 9:57 AM EDT - 5 weeks ago

Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model

Feb 19, 2026, 8:30 AM EST - 2 months ago

Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping

Feb 13, 2026, 8:31 AM EST - 2 months ago

Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC

Feb 9, 2026, 9:15 AM EST - 2 months ago

Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data

Jan 27, 2026, 10:36 AM EST - 3 months ago

Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons

Jan 26, 2026, 9:30 AM EST - 3 months ago

Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery

Dec 18, 2025, 9:00 AM EST - 4 months ago

Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance

Dec 9, 2025, 7:45 AM EST - 4 months ago

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market

Nov 25, 2025, 7:45 AM EST - 5 months ago

Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models

Nov 5, 2025, 9:22 AM EST - 6 months ago

Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy

Oct 30, 2025, 9:32 AM EDT - 6 months ago

Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds

Oct 16, 2025, 9:45 AM EDT - 6 months ago

Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics

Oct 16, 2025, 9:15 AM EDT - 6 months ago

Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement

Oct 6, 2025, 9:15 AM EDT - 7 months ago

Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline

Sep 30, 2025, 9:15 AM EDT - 7 months ago

Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense

Sep 25, 2025, 8:30 AM EDT - 7 months ago

Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships

Sep 24, 2025, 4:50 PM EDT - 7 months ago

Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split

Sep 11, 2025, 7:00 AM EDT - 8 months ago

Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics

Sep 9, 2025, 9:12 AM EDT - 8 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

SMMT

Sep 9, 2025, 8:47 AM EDT - 8 months ago

Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery

Sep 8, 2025, 8:50 AM EDT - 8 months ago

Lunai Bioworks Strengthens European Strategy Through Restructuring

Sep 4, 2025, 10:05 AM EDT - 8 months ago

Lunai Bioworks Inc. Retains American Defense International

Aug 27, 2025, 9:45 AM EDT - 8 months ago

Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics

Aug 8, 2025, 10:45 AM EDT - 9 months ago

Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks

Jul 28, 2025, 10:38 AM EDT - 9 months ago

Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector

Jul 17, 2025, 9:15 AM EDT - 10 months ago

Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

Jul 9, 2025, 8:00 AM EDT - 10 months ago

Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives

Jun 30, 2025, 9:21 AM EDT - 10 months ago

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

Jun 3, 2025, 9:15 AM EDT - 11 months ago

Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

May 22, 2025, 3:12 PM EDT - 1 year ago

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 22, 2025, 11:05 AM EDT - 1 year ago

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 14, 2025, 9:15 AM EDT - 1 year ago

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

May 13, 2025, 9:15 AM EDT - 1 year ago

Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics

Apr 22, 2025, 9:20 AM EDT - 1 year ago

Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

Apr 9, 2025, 9:25 AM EDT - 1 year ago

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

Apr 4, 2025, 9:40 AM EDT - 1 year ago

Renovaro Provides Update to Definitive Agreement with Predictive Oncology

Mar 3, 2025, 9:15 AM EST - 1 year ago

Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology

Feb 26, 2025, 1:25 PM EST - 1 year ago

Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

Feb 26, 2025, 9:15 AM EST - 1 year ago

Renovaro Announces $15 million in Equity Committed

Jan 7, 2025, 6:51 PM EST - 1 year ago

PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI

AGPU

Jan 7, 2025, 9:15 AM EST - 1 year ago

Renovaro Appoints Nathen Fuentes as Chief Financial Officer

Jan 7, 2025, 9:15 AM EST - 1 year ago

Renovaro Issues Shareholder Letter and Provides Corporate Update

Jan 6, 2025, 9:15 AM EST - 1 year ago

Renovaro to Acquire Predictive Oncology in All-Stock Transaction

Dec 30, 2024, 9:00 AM EST - 1 year ago

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Dec 23, 2024, 9:00 AM EST - 1 year ago

RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program

Dec 20, 2024, 3:40 PM EST - 1 year ago

Renovaro Regains Compliance with NASDAQ Listing Requirement

Dec 20, 2024, 9:00 AM EST - 1 year ago

Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

IcePhoenix Apr. 25 at 3:47 AM

0 · Reply

RoyalImperial Apr. 24 at 9:24 PM

0 · Reply

sidhero Apr. 24 at 4:36 PM

$LNAI what happened it was doing so well

0 · Reply

Kesiya Apr. 24 at 1:32 PM

$LNAI If it has already exited, do not buy again, friends (wait for a new post)/ but if it is still there, set a stop-loss at 3-5%.,

0 · Reply

Jumpmanz Apr. 24 at 1:28 PM

$ELPW $FCHL $ITOC $LNAI $SCNI

1 · Reply

Kesiya Apr. 24 at 1:23 PM

$FCHL $ITOC $LNAI /Get ready to travel+

1 · Reply

xMrCommonwealth Apr. 24 at 1:22 PM

$FCHL $SCNI $ELPW $ITOC $LNAI

1 · Reply

DavidScott Apr. 24 at 12:57 PM

$FCHL $SCNI $ELPW $ITOC $LNAI = Morning Movers 🔥📈💪

0 · Reply

Olivia_Strickland Apr. 24 at 12:46 PM

1 · Reply

Luvstocks26 Apr. 24 at 11:54 AM

0 · Reply

Kesiya Apr. 24 at 11:47 AM

$FCHL $ITOC $LNAI are being pressed down / but still strong, we can wait

0 · Reply

bjhbj Apr. 24 at 11:25 AM

$CTNT $LNAI let's go!

0 · Reply

Porto98 Apr. 24 at 11:11 AM

$LNAI

0 · Reply

gemstoneexplorer Apr. 24 at 10:21 AM

$LNAI

0 · Reply

bjhbj Apr. 24 at 10:01 AM

$CTNT “Next is $LNAI—please remember my post.”

0 · Reply

Aburose Apr. 24 at 9:53 AM

$LNAI Lunai Bioworks unit BioSymetrics signed a non-binding letter of intent with Geneial to pursue a strategic collaboration in rare neurological disorders. Partnership targets creation of trial-ready patient cohorts by integrating patient-led datasets across multiple registries with longitudinal clinical data. Companies aim to use resulting cohorts to support commercial partnerships with pharmaceutical and biotechnology groups, creating potential revenue-generating collaborations. Initial focus covers select rare neurodevelopmental disorders, with plans to expand program scope over time.

0 · Reply

Nataina Apr. 24 at 9:44 AM

$LNAI let’s see if it can hold !

0 · Reply

Kesiya Apr. 24 at 9:37 AM

$LNAI LNAI /A Zero Borrow Fee 103.15% Still strong / Don't forget our target

1 · Reply

Porto98 Apr. 24 at 9:36 AM

$LNAI

0 · Reply

Luvstocks26 Apr. 24 at 9:18 AM

$LNAI $1 by market open and then sky is the limit for the rest of day

0 · Reply

Plate32 Apr. 24 at 9:16 AM

$LNAI Something is happening

0 · Reply

Aburose Apr. 24 at 8:56 AM

$LNAI 500%

0 · Reply

Market Cap	7.37M
Revenue (ttm)	0.00
Net Income (ttm)	-178.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	29,815,000
Avg Vol	24,073,018
Day's Range	N/A - N/A
Shares Out	24.19M
Stochastic %K	45%
Beta	0.51
Analysts	Strong Buy
Price Target	N/A